When the Cure Contains the Contaminant
Hospitals are designed to heal, but they may inadvertently expose patients and healthcare workers to PFAS through a surprising array of medical products. From intravenous bags to surgical gowns, PFAS compounds have been incorporated into medical devices and materials for decades, leveraging their chemical resistance, lubricity, and non-stick properties. As PFAS regulation intensifies, the healthcare sector faces difficult tradeoffs between material performance and chemical safety.
Medical Devices: A Pervasive PFAS Presence
Polytetrafluoroethylene (PTFE), the most well-known PFAS compound commercially known as Teflon, is used extensively in medical devices due to its biocompatibility, lubricity, and chemical inertness. Catheter coatings, guidewires, surgical sutures, vascular grafts, cardiac patches, and implantable devices all commonly incorporate PTFE or related fluoropolymers. While PTFE polymers are considered lower-risk than mobile PFAS molecules due to their high molecular weight, manufacturing processes introduce smaller PFAS compounds that may migrate into biological tissues.
IV bags—polyvinyl chloride pouches used to deliver fluids directly into patients’ bloodstreams—have been found to contain PFAS processing aids. A 2022 study in Environment International detected multiple PFAS compounds migrating from IV tubing and bags into saline solutions, particularly when heated or stored for extended periods. For critically ill patients receiving continuous IV therapy, cumulative PFAS exposure from this pathway alone may be clinically meaningful.
Healthcare Worker Exposure
Surgical gowns, drapes, and personal protective equipment (PPE) used in operating rooms are commonly treated with durable water repellent (DWR) PFAS coatings to resist blood and fluid penetration. Healthcare workers handling these garments repeatedly throughout shifts accumulate dermal and inhalation exposures. Sterilization processes—particularly high-temperature steam autoclave cycles—may volatilize some PFAS compounds, creating localized air quality concerns in sterile processing departments.
Hospital carpeting and furnishings in waiting areas and patient rooms are frequently treated with PFAS stain-resistant coatings. Floor wax formulations used in hospital corridors have historically contained PFAS as leveling agents. The aggregate PFAS burden in healthcare environments likely exceeds most other commercial settings.
Regulatory Movement in Healthcare PFAS
The U.S. FDA has begun requiring PFAS disclosure for certain medical devices under new chemical reporting frameworks. The EU’s Medical Devices Regulation (MDR) has prompted manufacturers to evaluate PFAS use in Class II and Class III devices. Several major healthcare systems—including Kaiser Permanente and Health Care Without Harm member organizations—have adopted PFAS procurement restrictions, prioritizing suppliers who can certify PFAS-free or PFAS-reduced product alternatives.
For patients undergoing extended hospitalization, particularly neonates in NICUs connected to multiple PFAS-containing devices, the cumulative exposure question remains open. Research into PFAS migration rates from medical devices into biological matrices is accelerating, but regulatory guidance specific to healthcare PFAS exposures remains nascent.